Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.67 |
| ▸ | MAOB | P27338 | 5/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | MAOA | P21397 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | AR | P10275 | 1/20 | 0.62 |
| ▸ | BCHE | P06276 | 1/20 | 0.60 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10128671 | 0.94 | LMNA (0.60) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL8736979 | 0.94 | LMNA (0.60) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL11611966 | 0.92 | LMNA (0.58) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL2339524 | 0.91 | MAOB (0.65) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL14176678 | 0.89 | MEN1 (0.55) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL8737849 | 0.89 | AR (0.65) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL8929713 | 0.89 | MAOB (0.69) | MAOBMAPTMAOARAB9ASMN1; SMN2 | |
| SCHEMBL891195 | 0.89 | MAOB (0.69) | MAOBMAPTMAOARAB9ASMN1; SMN2 | |
| SCHEMBL762195 | 0.89 | MAOB (0.69) | MAOBMAPTMAOARAB9ASMN1; SMN2 | |
| SCHEMBL8930213 | 0.89 | MAOB (0.69) | MAOBMAPTMAOARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 705 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107356682-B | HPLC method for detecting 4-benzyloxy benzylidene aniline in 4-benzyloxy benzylidene-4-fluoroaniline | 先声药业有限公司 | 2021-06-29 | — | — | CN | claimed |
| CN-112209900-A | Method for preparing 4-cyclohexylmorpholine compound by using lignin model compound | 华东师范大学 | 2021-01-12 | — | — | CN | claimed |
| CN-107356682-A | A kind of HPLC methods of 4- benzyloxy benzylidene anilines in detection 4- benzyloxy benzylidene -4- fluoroanilines | 南京先声东元制药有限公司 | 2017-11-17 | — | — | CN | claimed |
| CN-102325659-B | Novel color-forming compounds and use thereof in imaging members and methods | ZINK IMAGING INC | 2015-04-01 | — | — | CN | claimed |
| US-20090215783-A1 | COMPOSITION FOR INDUCTION OR INHIBITION OF STEM CELL DIFFERENTIATION | CHOONGWAE PHARMA CORPORATION (KR) | 2009-08-27 | — | — | US | claimed |
| CN-101495120-A | Composition for induction or inhibition of stem cell differentiation | CHOONGWAE PHARMA CORP (KR) | 2009-07-29 | — | — | CN | claimed |
| EP-2029142-A1 | COMPOSITION FOR INDUCTION OR INHIBITION OF STEM CELL DIFFERENTIATION | Choongwae Pharma Corporation (KR) | 2009-03-04 | — | — | EP | claimed |
| WO-2007139346-A1 | COMPOSITION FOR INDUCTION OR INHIBITION OF STEM CELL DIFFERENTIATION | CHOONGWAE PHARMA CORPORATION (KR) | 2007-12-06 | — | — | WO | claimed |
| US-6806384-B2 | VIA TREATING N-CARBAMATE-PROTECTED BETA-AMINOEPOXIDE WITH ACID FORMING 5-HYDROXYMETHYL-2-OXAZOLIDINONE, THEN OXIDIZING IN 2,2,6,6-TETRAMETHYL-1-PIPERIDINYLOXY AND HYPOCHLORITE FORMING 4-BENZYL-2-OXO-5-OXAZOLIDINECARBOXYLIC ACID; CRYSTALLIZATION | AJINOMOTO CO., INC. (JP) | 2004-10-19 | — | — | US | claimed |
| US-6630512-B2 | Antiinflammatory agents; autoimmune disease | BIOGEN, INC. | 2003-10-07 | — | — | US | claimed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | claimed |
| EP-0796239-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE (S,S) AMINOEPOXIDES, KEY INTERMEDIATES FOR HIV PROTEASE INHIBITORS, VIA THEIR CHLOROHYDRINES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1997-09-24 | — | — | EP | claimed |
| US-5550291-A | Process for key intermediates for HIV protease inhibitors | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH, INC. (CA) | 1996-08-27 | — | — | US | claimed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | claimed |
| WO-1996017821-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE (S,S) AMINOEPOXIDES, KEY INTERMEDIATES FOR HIV PROTEASE INHIBITORS, VIA THEIR CHLOROHYDRINES | BOEHRINGER INGELHEIM (CANADA) LTD./BOEHRINGER INGELHEIM (CANADA) LTÉE (CA) | 1996-06-13 | — | — | WO | claimed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | claimed |
| EP-0126974-B1 | CARBOXYALKYL PEPTIDE DERIVATIVES | G.D. Searle & Co. (US) | 1988-06-15 | — | — | EP | claimed |
| EP-0126974-A1 | Carboxyalkyl peptide derivatives | G.D. Searle & Co. (US) | 1984-12-05 | — | — | EP | claimed |
| US-4029690-A | WITH 2,5-DIMETHYL-2,4-HEXADIENE AND AN ALKYL DIAZOACETATE WITH A COPPER COMPLEX CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1977-06-14 | — | — | US | claimed |
| US-4029683-A | WITH A SCHIFF BASE, CHRYSANTHEMATE SYNTHESIS CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1977-06-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215783-A1 | COMPOSITION FOR INDUCTION OR INHIBITION OF STEM CELL DIFFERENTIATION | MYLK2, TNNC1, MYH2 | LMNA 194/4885CYP1A2 3259/4885PTGS1 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.